Lung cancer is the top cause of cancer-related mortalities in Australia with 14,500 new cases each year. Credit: PeopleImages.com – Yuri A/Shutterstock.

Australia’s Therapeutic Goods Administration (TGA) has approved Body Vision Medical’s AI-powered advanced imaging system, LungVision, intended to improve the early diagnosis of lung cancer.

LungVision is designed to transform any C-arm [an advanced medical imaging device based on x-rays] into a three-dimensional imaging system, providing physicians with real-time navigation and improved visualisation for accurate bronchoscopic biopsies.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Its tablet interface allows for comprehensive control of the system, which includes planning and managing procedures from anywhere in the room.

The company has confirmed a collaboration with ParagonCare to distribute the system in New Zealand and Australia.

ParagonCare Capital and Service general manager Tiffany Chiew stated: “We are excited to welcome Body Vision Medical’s technology to our portfolio, as it strengthens our commitment to advancing augmented lung and respiratory medicine through cutting-edge AI.

“Body Vision’s real-time imaging technology offers remarkable opportunities, significantly enhancing the chances for earlier cancer detection and ultimately improved lung cancer survival rates.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The system is compatible with any C-arm fluoroscope, enabling the generation of intra-procedural images that are essential for the identification of lung nodules.

Lung cancer is the top cause of cancer-related mortalities in Australia, with 14,500 new cases each year.

In July 2024, the LungVision system gained an innovative technology contract from provider-driven healthcare performance improvement company Vizient. The contract was supported by the recommendations from hospital experts on Vizient’s customer-led councils.

The company established exclusive distribution agreements with Paragon Care, Kral Medical Solutions and Prism Technologies for LungVision in August 2023.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact